Results: DCTA

Search articles by EPIC code
EPIC DCTA
views

Directa Plus – argues “continues to perform strongly”. Does it?

Writing on company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) earlier this week, I noted US patents development and “generating considerable interest”, but what about the financials?. So what of now a “pleased to provide… trading update ahead of the announcement of its half year results for the six months to 30 June 2022 on 29 September”?

EPIC DCTA
views

Directa Plus – US patents development and “generating considerable interest”, but what about the financials?

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+ embedded polyurethane membrane”, with the offering “generating considerable interest in the US market”. So what of a current 90p share price?

EPIC DCTA
views

Directa Plus – 2021 results, how “comfortable” with forecasts?...

Producer and supplier of graphene nanoplatelets-based products Directa Plus (DCTA) has announced 2021 results emphasising “revenue and profitability which have exceeded consensus market expectations” and “a number of exciting opportunities in our targeted markets”. So what of a current 121.5p share price?...

Page 1 of 3 (24 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments